Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4503-4508

  Hoffmann, Katrin ^a   Franz, Clemens ^a   Xiao, Zhi ^a   Mohr, Elvira ^a   Serba, Susanne ^a   Büchler, Markus W ^a   Schemmer, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemosensitivity sorafenib; Hepatocellular carcinoma cells; Multidrug resistance; P glycoprotein; Tyrosine kinase pathway

Indexed keywords

ABC TRANSPORTER; DOXORUBICIN; GEMCITABINE; MESSENGER RNA; SORAFENIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL SURVIVAL; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MONOTHERAPY; MULTIDRUG RESISTANCE; NITROBLUE TETRAZOLIUM TEST; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DEOXYCYTIDINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 78650247661     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108, 2005.
2. Llovet JM and Bruix J: Hepatocellular carcinoma. The Lancet 362: 1907-1917, 2003.
3. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236, 2005.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M and Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3): 421-430, 2001.
5. Ganne-Carrie N and Trinchet JC: Systemic treatment of hepatocellular carcinoma. Eur J Gastroent and Hepatol 16(3): 275-281, 2004.
6. Lopez PM, Villanueva A and Llovet JM: Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23(11): 1535-1547, 2006.
7. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ and Keppler D: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94(4): 492-499, 2001.
8. Li B, Ye T, Zhao L, Li DH, Gou XH, Zhao LY, Han L, Chen L, Yan LN and Gong JP: Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 5(4): 552-559, 2006.
9. Borst P and Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592, 2002.
10. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H and Trauner M: Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25(2): 367-379, 2005.
11. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, Shimizu H, Yokosuka O and Nakajima N: Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 78(2): 110-115, 2001.
12. Soini Y, Virkajarvi N, Raunio H and Paako P: Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49: 470-473, 1996.
13. Vander BS, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F and Roskams T: Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28(10): 1370-1380, 2008.
14. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O and Breier A: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 14(1): 29-36, 2001.
15. Garcia R, Franklin RA and McCubrey JA: EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5(23): 2820-2826, 2006.
16. Guan J, Chen XP, Zhu H, Luo SF, Cao B and Ding L: Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol 10(23): 3522-3527, 2004.
17. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6(7): 2092-2102, 2007.
18. Hoffmann K, Xiao Z, Franz C, Mohr E, Schultze D, Serba S, Büchler MW and Schemmer P: Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in experimental hepatocellular carcinoma. Unpublished data.
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul JP and Zeuzem S: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo controlled trial. J Clin Oncol 25: LBA1, 2007.
20. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Voigtmann R, Schwartz B, Brendel E, Christensen O, Haase CG and Stuart-Harris H: Results of a phase I trial of Bay 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clinical Pharmacol 42(11): 650-651, 2004.
21. Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, Voliotis D, Schwartz B and Brendel E: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther 41(12): 618-619, 2003.
22. Nakabayashi H, Taketa K, Miyano K, Yamane T and Sato J: Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42(9): 3858-3863, 1982.
23. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209(4455): 497-499, 1980.
24. Herr I, Schemmer P and Buchler MW: On the TRAIL to therapeutic intervention in liver disease. Hepatology 46(1): 266-274, 2007.
25. Villanueva A, Toffanin S and Llovet JM: Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 20(4): 444-453, 2008.
26. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P and Stuart K: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12): 1898-1903, 2006.
27. Yang JM, Sullivan GF and Hait WN: Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53(11): 1597-1604, 1997.
28. Yang JM, Vassil AD and Hait WN: Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60(4): 674-680, 2001.
29. Azzariti A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, Berardi F, Perrone R, Zucchetti M, D'Incalci M, Xu JM and Paradiso A: Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol 65(2): 335-346, DOI: 10.1007/560280-009-1039-0.
30. Gnoth MJ, Sandmann S, Engel K and Radtke M: In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 38(8): 1341-1346, 2010.
31. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Kredtke S, Voliotis D, Scheulen ME, Seeber S and Strumberg D: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 41(12): 620-621, 2003.
32. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K and Bonavida B: Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91: 169-200, 2004.
33. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV and McCubrey JA: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9(3): 1161-1170, 2003.
34. Kim SH, Lee SH, Kwak NH, Kang CD and Chung BS: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98(2): 199-205, 1996.
35. Li L, Jiang AC, Dong P, Wang H, Xu W and Xu C: MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 16(5): 1421-1428, 2009.
36. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Voigtmann R, Schwartz B, Brendel E, Christensen O, Haase CG and Strumberg D: Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 42(11): 650-651, 2004.
37. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De GJ, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26): 4293-4300, 2006.
38. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
39. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C and Rosmorduc O: Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for retargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15(17): 5445-5456, 2009.